Lv4
696 积分 2025-11-14 加入
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
1个月前
已完结
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
1个月前
已完结
Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective
6个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
6个月前
已完结
Acalabrutinib alleviates metabolic dysfunction–associated steatotic liver disease by regulating bile acid metabolism
6个月前
已完结
The current and future landscape of Bruton’s tyrosine kinase inhibitors in allergy
6个月前
已完结
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
6个月前
已完结
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
6个月前
已完结
Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors
7个月前
已完结
Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
7个月前
已完结
皖公网安备34019202002308
